Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

re were no drug-related serious adverse events and no adverse events were considered to be definitely or probably related to study treatment. In the multiple ascending dose studies all possibly-related adverse events were mild in severity and resolved spontaneously.

"We're very encouraged with the results of the ex vivo response study that suggest a majority of Pompe patients may be treatable with our pharmacological chaperone AT2220," said John F. Crowley, President and CEO of Amicus Therapeutics. "Based on these data and the safety data from the Phase 1 studies, we look forward to commencing a Phase 2 clinical trial in Pompe patients the first half of this year."

As of November 2007, AT2220 is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Pompe Disease

Pompe disease affects an estimated 5,000-10,000 patients worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive weakness and respiratory insufficiency. A high majority of patients have the late onset form of the disease. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the tre
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:8/30/2014)... Calif. (PRWEB) August 30, 2014 Insomnia causes ... helps listeners understand how they unknowingly developed insomnia and the ... restful nights during. Tune in to the show at ... The show airs live on August 30, and will be ... information on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia ...
(Date:8/30/2014)... Randy Dotinga HealthDay ... About one in five patients operated on for broken bones ... surgery, a new study finds. Less-educated patients and ... more likely to be "doctor shoppers," said study lead author ... Ky. Overall, he said, the study suggests that doctors aren,t ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Hastings and ... injury attorneys located throughout Arizona is pleased to report ... is one specific example among many cases where Hastings ... are able to retain a greater portion of their ... case that providing a positive solution for Arizona car ...
(Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
(Date:8/30/2014)... 2014 "My niece developed a nighttime ... any moment, her fever might get worse," said an ... well aware of how she was doing, I developed ... to continuously monitor a child's temperature. The unit instantly ... ensures that prompt medical care can be given, which ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... closely watching the developments in a little-known southwestern Ontario ... vaccine-related exposure among its members. // ,This ... the United States. Health officials are not disclosing the ... thought to be in close vicinity of the Middlesex ...
... is on track to roll-out a nationwide screening programme ... infertility in both sexes//. ,So far nearly 80,000 ... difficult to detect but is easy to cure, following ... Programme (NCSP). ,There has been a heightened concern ...
... is a very famous saying which refers to an attitude ... achieve it and so feign that we are not concerned ... Everybody knows it's good; yet many people still avoid it, ... above statement researchers at the University of Illinois at Urbana-Champaign ...
... As per a Goldman Sachs report, bird flu may reduce ... is easily transmitted among humans, possibly by more than 1-million ... barrels a day, according to data issued by the US ... true global pandemic, the economic implications would be profound, potentially ...
... The FDA has sent shock waves in the industry ... Nov. 8 from the U.S. Food and Drug Administration ... for qualified health claims for lycopene, tomatoes, and tomatoes-based ... lycopene (tomatoes, tomato-based foods containing lycopene) may reduce the ...
... found that less volume of white matter in the frontal lobe ... of decline in brain activity//. The researchers have found that the ... related but due to not using the white matter (frontal lobe) ... the left side of the brain which contains the Grey matter ...
Cached Medicine News:Health News:UK Govt Says On Course For National Chlamydia Screening 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 2Health News:Important parameters of life: Longevity and quality: both improved by exercise 3Health News:Bird Flu Likely To Reduce World Energy Demand 2
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: